These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 20597656)

  • 1. Scenario 2: A patient with ventilator-associated bacterial pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S100-2. PubMed ID: 20597656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scenario 1: a patient with hospital-acquired bacterial pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S10-1. PubMed ID: 20597655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Registration trials of antibacterial drugs for the treatment of nosocomial pneumonia.
    Sorbello A; Komo S; Valappil T; Nambiar S
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S36-41. PubMed ID: 20597669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges in the design and conduct of clinical trials for hospital-acquired pneumonia and ventilator-associated pneumonia: an industry perspective.
    Barriere SL
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S4-9. PubMed ID: 20597670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia.
    Kollef MH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S29-35. PubMed ID: 20597668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospital-acquired pneumonia, health care-associated pneumonia, ventilator-associated pneumonia, and ventilator-associated tracheobronchitis: definitions and challenges in trial design.
    Niederman MS
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S12-7. PubMed ID: 20597660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of severity scoring and stratification factors in clinical trials of hospital-acquired and ventilator-associated pneumonia.
    Napolitano LM
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S67-80. PubMed ID: 20597675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Considerations unique to pediatrics for clinical trial design in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bradley JS
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S136-43. PubMed ID: 20597664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia.
    Bartlett JG; Barie PS; Niederman MS; Wunderink RG
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-3. PubMed ID: 20597654
    [No Abstract]   [Full Text] [Related]  

  • 11. Surrogate markers and microbiologic end points.
    Wunderink RG
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S126-30. PubMed ID: 20597662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End points in hospital-acquired pneumonia and/or ventilator-associated pneumonia clinical trials: food and drug administration perspective.
    Laessig KA
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S117-9. PubMed ID: 20597659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health care-associated infections studies project: Case 3.
    Wright MO; Hebden JN; Allen-Bridson K; Morrell GC; Horan T
    Am J Infect Control; 2010 Oct; 38(8):642-3. PubMed ID: 20739097
    [No Abstract]   [Full Text] [Related]  

  • 14. Issues in the design of clinical trials for antibacterial drugs for hospital-acquired pneumonia and ventilator‐associated pneumonia. Proceedings of a workshop co-sponsored by the US Food and Drug Administration, Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine. March 31-April 1 2009.
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S1-170. PubMed ID: 21058464
    [No Abstract]   [Full Text] [Related]  

  • 15. Prevention of ventilator-associated pneumonia in the cardiothoracic intensive care unit: back to basics.
    Andersen ND
    J Thorac Cardiovasc Surg; 2014 Dec; 148(6):3155-6. PubMed ID: 25439788
    [No Abstract]   [Full Text] [Related]  

  • 16. Strategy of antibiotic rotation: long-term effect on incidence and susceptibilities of Gram-negative bacilli responsible for ventilator-associated pneumonia.
    Gruson D; Hilbert G; Vargas F; Valentino R; Bui N; Pereyre S; Bebear C; Bebear CM; Gbikpi-Benissan G
    Crit Care Med; 2003 Jul; 31(7):1908-14. PubMed ID: 12847382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Powers JH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1(Suppl 1):S18-28. PubMed ID: 20597667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Year in Review IV: Interstitial lung disease, cystic fibrosis, pulmonary infections, and mycobacterial disease.
    Tino G
    Proc Am Thorac Soc; 2006 Nov; 3(8):650-3. PubMed ID: 17065369
    [No Abstract]   [Full Text] [Related]  

  • 19. Management of ventilator-associated pneumonia.
    Diaz E; Ulldemolins M; Lisboa T; Rello J
    Infect Dis Clin North Am; 2009 Sep; 23(3):521-33. PubMed ID: 19665081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations in undertaking a clinical development program for hospital-acquired bacterial pneumonia and/or ventilator-associated bacterial pneumonia.
    Talbot GH
    Clin Infect Dis; 2010 Aug; 51 Suppl 1():S144-9. PubMed ID: 20597665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.